# Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer

Source: https://onco.cc/trials/nct06205836/  
OnCo record `nct06205836` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of cemiplimab and fianlimab in colorectal cancer, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, now recruiting.

## Summary

Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer is a phase 2, interventional study registered as NCT06205836 by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, with a registry enrolment figure of 44 participants, started 2024-06-13 and due to reach its primary completion in 2030-05. Interventions recorded: Cemiplimab; Fianlimab. Conditions listed: Colorectal Cancer. Primary outcome: Complete Response Rate. Colorectal eligibility wording from the registry: "* Have histologically proven localized or locally advanced mismatch repair deficient (dMMR) or microsatellite unstable (MSI-H) colorectal cancer". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT06205836
- Phase: 2
- Setting: Evaluating a Surgical-Sparing Approach Using Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer
- Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Enrolled: 44

## Sources

- ClinicalTrials.gov NCT06205836: https://clinicaltrials.gov/study/NCT06205836

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Mismatch-repair deficient (MSI-high) colorectal cancer](https://onco.cc/cancers/msi-high-colorectal/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Cemiplimab](https://onco.cc/drugs/cemiplimab/), [Fianlimab](https://onco.cc/drugs/fianlimab/)
- companies: [Regeneron](https://onco.cc/companies/regeneron/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06205836.json